Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2025

Segment Reporting

Schedule of certain segment information

The following table includes certain segment information for the periods presented (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Grant and award revenue	$	2,169	$	-	$	2,660	$	966
Operating expenses
Research and development expenses:
AP-PA02: Non-Cystic Fibrosis Bronchiectasis		152		1,768		(288)		3,602
AP-PA02: Cystic Fibrosis		14		138		25		235
AP-SA02: Bacteremia		1,011		1,051		1,663		1,134
AP-SA02: Prosthetic Joint Infection		1		1		2		8
Expenses not allocated by projects*		592		544		1,112		1,176
Total external research and development expenses		1,770		3,502		2,514		6,155
Research and development personnel expenses		2,293		2,809		4,606		5,422
Other research and development expenses		2,331		2,164		4,703		4,914
Total research and development expenses		6,394		8,475		11,823		16,491
General and administrative expenses:
General and administrative personnel expenses		1,191		1,571		2,592		2,505
Other general and administrative expenses		1,428		1,868		3,280		4,112
Total general and administrative expenses		2,619		3,439		5,872		6,617
Total operating expenses		9,013		11,914		17,695		23,108
Operating loss		(6,844)		(11,914)		(15,035)		(22,142)
Other income (expense), net		(9,451)		20,900		(7,791)		6,107
Net income (loss)	$	(16,295)	$	8,986	$	(22,826)	$	(16,035)